Latest Articles
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has shown sustained and clinically significant weight loss in the general population. There are limited data on outcomes of its use ...
Background Inflammatory bowel diseases (IBDs) pose a significant challenge due to their diverse, often debilitating, and unpredictable clinical manifestations. The absence of prognostic tools to ...
Background Inflammatory bowel diseases (IBDs) are incurable diseases that require lifelong access to health services. Accumulating evidence of inequalities in health care access, experience, and ...
Background Crohn’s disease (CD) is a progressive, destructive, and disabling disorder. Our study aimed to assess changes over time in the Lémann index (LI) and the Inflammatory Bowel Disease ...
In steady state, intestinal subepithelial myofibroblasts form a thin layer below the basement membrane. Unlike the rest of the stromal cells in the lamina propria, they express tensile proteins, ...
Editor's Choice Articles
Background Primary sclerosing cholangitis (PSC) is a chronic, fibroinflammatory, cholestatic liver disease of unknown etiopathogenesis, often associated with inflammatory bowel diseases. Recent ...
Background Stress reactivity (SR) is associated with increased risk of flares in ulcerative colitis (UC) patients. Because both preclinical and clinical data support that stress can influence gut ...
Background and Aims Inflammatory bowel disease (IBD) is a prevalent chronic noncurable disease associated with profound metabolic changes. The discovery of novel molecular indicators for unraveling ...
In this prospective study, patients with active ulcerative colitis receiving systemic corticosteroids were included (n = 93). Baseline microbial diversity and composition were associated with response to treatment only in biologic-naïve patients. Responders experienced longitudinal restoration of microbial composition and function.
Background Beyond systematic reviews and meta-analyses, there have been no direct studies of serological response to COVID-19 in patients with inflammatory bowel disease (IBD) across continents. In ...
Background Patients with ulcerative colitis (UC) may be prone to colitis-associated colorectal cancer (CAC), but there is still a poor understanding of the underlying mechanism so far. This study ...
Background The Ulcerative Colitis (UC) Narrative global survey assessed aspects of living with UC. This analysis aimed to identify health care disparities, social determinants of health, and ...
Background Therapeutic drug monitoring provides important guidance for treatment of patients with inflammatory bowel disease (IBD) and could help to early identify treatment failure. This study aimed ...
Journal Information
Impact Factor
4.9
Editor-in-Chief
Fabio Cominelli, M.D., Ph.D.
Deputy Editor
Sonia Friedman, M.D.
Publish with IBD
Inflammatory Bowel Diseases publishes original basic science, translational, and clinical research regarding pathogenesis, epidemiology, evaluation, and treatment of IBD that will lead to advancements in overall clinical care. Submit your article to contribute to this leading body of research.
Featured Videos
Video abstract
Thiopurine treatment in ulcerative colitis: a critical review of the evidence for current clinical practice
Video abstract
A survey study of gastroenterologists' attitudes and barriers towards therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease
Video abstract
Indeterminate QuantiFERON-TB gold increases likelihood of inflammatory bowel disease treatment delay and hospitalization
Video abstract
Factors associated with length of stay in veterans with inflammatory bowel disease hospitalized for an acute flare
Email alerts
Register to receive table of contents email alerts as soon as new issues of Inflammatory Bowel Diseases are published online.
Read and Publish deals
Authors interested in publishing in Crohn's & Colitis 360 may be able to publish their paper Open Access using funds available through their institution’s agreement with OUP.
Want access to IBD?
Fill out our simple online form to recommend IBD to your library. Your institution could also be eligible for free or deeply discounted access via our developing countries initiatives.
About the Foundation
Professional Education Opportunities
The Foundation is here to support healthcare providers in their efforts to care for patients with IBD through our professional education and training programs. Learn more about our many resources for professionals as well as educational activities.
Connect with the Foundation
Stay up to date with the latest news and content from the Foundation:
Become a Foundation Member
By becoming a Professional Member of the Crohn's & Colitis Foundation, you will establish yourself as a leader and specialist in Crohn's disease and ulcerative colitis. In addition, you will gain the support and resources that can help you equip your patients with everything they need to take charge of their digestive diseases.
Learn moreResources to Share
As the nation’s leading source for educational information for Crohn’s disease and ulcerative colitis patients and professionals, the Crohn’s & Colitis Foundation maintains an extensive collection of resources for people diagnosed with these diseases, and other information on IBD.
Learn more
